Respiri announces strategic Advisor appointments as it pushes for global rollout of Wheezo
Health & Biotech
Health & Biotech
Link copied to
The company’s flagship product Wheezo has received US FDA clearance, with a UK launch scheduled for the end of the year.
eHealth MedTech company, Respiri (ASX:RSH), has appointed strategic advisors in Australia and the UK, as part of its plans to roll out its flagship product, Wheezo.
In Australia, the company has just appointed medical director with extensive experience in respiratory medicine, Dr Andrew Weekes, as an advisor to its board. Dr Weekes is a UK-trained doctor with over 20 years’ experience in global roles, including pharmaceutical companies AbbVie and Servier.
He is currently the Country Medical Director for global giant GlaxoSmithKline Australia and has substantial experience in respiratory medicine, rolling out company medical education programs, as well as having extensive global connections in the healthcare industry.
His appointment comes as the company prepares for a Wheezo launch in the UK later this year and continues to ramp up its activities in Australia.
Mr Marjan Mikel, CEO of Respiri says Dr Weekes’ “substantial experience within a leading pharma company along with his global experience including the UK, harmonises with our preparations and plans for a UK launch, which have now commenced and remain on- track for a Q4 2021 launch in that important asthma market and also our immediate commercial ambitions in Australia.”
The appointment is timed to coincide with the hiring of another expert, Dr Mark Levy, as an advisor to the Company in the UK.
Dr Levy has been a board member of GINA (Global Initiative for Asthma) since 2009 and will play a pivotal role in providing immediate key advice and introductions for the imminent UK launch later this year.
The two advisors will align their expertise and provide the company advice on the commercialisation and clinical development of Wheezo.
Wheezo is an innovative asthma management solution that assists asthma patients with the management their condition, especially children and adolescents.
The device has just been granted 510(k) clearance from the US Food and Drug Administration, permitting the company to market and sell the wheeze detector and associated smartphone app as an Over the Counter (OTC) class II medical device. This means that it can be sold without subscription through pharmacy, retail, and online channels but also as a prescription product which allows Respiri to take advantage of the physician driven Remote Patient Monitoring Current Procedural Terminology (CPT) reimbursement codes in the US. Wheezo is one of the few eHealth devices that has this commercial scope.
The UK launch is already in motion, with Respiri currently in talks with Cipla and other potential partners.
It’s also in advanced discussions with key clinicians in the UK on asthma-related studies, and on the role of advanced digital technologies used in paediatric asthma in the UK.
These discussions, Respiri says, will build awareness and educate clinicians in the UK, and offer further scientific evidence for the technology’s inclusion into the asthma care quality standards issued by the National Institute for Health and Care Excellence.
The Respiri share price has risen by 80 per cent in the past year.
This article was developed in collaboration with Respiri, a Stockhead advertiser at the time of publishing.
This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.